Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01932710 · ClinicalTrials.gov registry record · Phase 2
A Feasibility Study of Prophylactic White Blood Cell Transfusions
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT01932710: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01932710 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 45 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01932710, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
Patients with leukemia often have low white blood cell counts after chemotherapy, which puts them at greater risk of infection. The standard of care for preventing infections is to give these patients antibiotic, antifungal, and antiviral drugs during the time that white blood cell counts are low. However, many patients still develop infections during chemotherapy. Radiated white blood cell transfusions are a standard treatment once a patient develops a severe infection. The goal of this clinical research study is to learn if giving white blood cell transfusions that are not radiated early in chemotherapy might delay or prevent infections in patients with leukemia. Researchers also want to learn more about the type and severity of any infections that do occur.
Interventions
- PROCEDURE White Blood Cell Transfusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2013-09-20 |
| Est. Completion | 2016-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01932710
The ClinicalTrials.gov registry entry for NCT01932710 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which White Blood Cell Transfusion is the first listed.
NCT01932710 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01932710 about?
NCT01932710 is a clinical study titled "A Feasibility Study of Prophylactic White Blood Cell Transfusions". Patients with leukemia often have low white blood cell counts after chemotherapy, which puts them at greater risk of infection. The standard of care for preventing infections is to give these patients antibiotic, antifungal, and antiviral drugs during the time that white blood cell counts are low. H...
What is the current status of trial NCT01932710?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2013-09-20. Estimated completion is 2016-11-30.
What interventions are being tested in trial NCT01932710?
The interventions under investigation include: White Blood Cell Transfusion (PROCEDURE).
Who is sponsoring clinical trial NCT01932710?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.